Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC004207 | Panoply™ Human DEK Knockdown Stable Cell Line | Inquiry |
| CSC-SC004207 | Panoply™ Human DEK Over-expressing Stable Cell Line | Inquiry |
| CLKO-0895 | DEK KO Cell Lysate-HEK293T | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD04771Z | Human DEK adenoviral particles | Inquiry |
| LV10584L | human DEK (NM_001134709) lentivirus particles | Inquiry |
| LV10585L | human DEK (NM_003472) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH001153 | shRNA set against Rat Dek(NM_001004255.1) | Inquiry |
| SHH001171 | shRNA set against Human DEK(NM_003472.3) | Inquiry |
| SHH276981 | shRNA set against Human DEK (NM_003472.3) | Inquiry |
| SHH276985 | shRNA set against Mouse DEK (NM_025900.2) | Inquiry |
| SHH276989 | shRNA set against Rat DEK (NM_001004255.1) | Inquiry |
| SHW000874 | shRNA set against Chicken DEK (NM_001012560) | Inquiry |
| SHW010159 | shRNA set against Danio rerio DEK (NM_001045276) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFH004976 | Human DEK cDNA Clone(NM_001134709.1) | Inquiry |
| CDFR001402 | Rat Dek cDNA Clone(NM_001004255.1) | Inquiry |
| MiUTR1H-02768 | DEK miRNA 3'UTR clone | Inquiry |
| MiUTR1R-01464 | DEK miRNA 3'UTR clone | Inquiry |
| MiUTR3H-00642 | DEK miRNA 3'UTR clone | Inquiry |
| SKO0427 | DEK Validated sgRNA vector | Inquiry |
| CDCB158682 | Human DEK ORF clone (BC035259) | Inquiry |
| CDCB162349 | Chicken DEK ORF Clone (NM_001012560) | Inquiry |
| CDCB171634 | Danio rerio DEK ORF Clone (NM_001045276) | Inquiry |
| CDCB193307 | Rabbit DEK ORF clone (XM_002720860.2) | Inquiry |
| CDCR054876 | Human DEK ORF clone (NM_001134709.1) | Inquiry |
| CDCR257809 | Mouse Dek ORF Clone(NM_025900.2) | Inquiry |
| CDCR285688 | Human DEK ORF Clone(NM_003472.3) | Inquiry |
| CDCR368453 | Rat Dek ORF Clone(NM_001004255.1) | Inquiry |
| CDCS408020 | Human DEK ORF Clone (BC035259) | Inquiry |
DEK is a strongly conserved nuclear factor and the only member of its class of proteins expressed primarily in proliferatively active and pernicious cells, with up to 4-6 million copies of DEK per cell nucleus. DEK was originally described as a target of recurrent translocations in patients with acute myeloid leukemia (AML). Subsequently, DEK has been shown to promote tumorigenesis in a variety of cancer cell types, at least in part because it disrupts cell division or DNA repair, inhibits cell differentiation, senescence, and apoptosis, and cooperates with transforming oncogenes.
Structure and Function of DEK
The majority of DEK binds to chromatin, mainly in the euchromatin region of chromatin, but can also be found in the nuclear matrix or in clusters of interchromatin granules. Although DEK exhibits some sequence-specific DNA binding, it seems to recognize mainly structural features (cruciform and super helical DNA). DEK has two major structural domains responsible for interaction with DNA. Residues 87 to 187 are homologous to the structural domain of the scaffold attachment factor box (SAF-box) found in several nuclear proteins. The second domain, composed of residues 270 to 350 in the carboxy-terminal region of the DEK protein, is also responsible for multimerization. Although the most well-known oncogenic property of DEK is related to DNA binding, a portion of DEK (about 10%) is associated with RNA and regulates RNA processing. Thus, DEK can influence the recognition of the 3' splice site by the splicing factor U2AF. In addition, DEK interacts with SR (serine/arginine-rich) proteins and other factors involved in the exon-exon junction complex, but the functional relevance of these interactions in cancer remains to be clarified.
Role of DEK in Tumor Progression and Drug Response
DEK has been implicated in tumor development. In malignant myeloid cells, DEK-NUP214 exposure is associated with a generalized activation of protein synthesis and increased phosphorylation of eIF4E, a key factor in transmission initiation and a marker of translational activity. In conclusion, the DEK-NUP214 fusion protein was found to be impaired in its ability to bind to histones and its translational activity in 293T cells was also affected. ability to bind to histones and to be phosphorylated by CK2α and CK2β.
DEK Works as A Drug Target
DEK is an abundant polymitotic factor that binds to large swaths of chromatin. Interfering with DEK function can cause intolerable side effects in normal cells. However, the fact that DEK-deficient mice survive and DEK-deficient tumor cells go into senescence or apoptosis is evidence of a DEK-dependent "carcinogenic addiction." The feasibility and efficacy of sustained down-regulation of DEK in physiologically relevant tumor models or clinical settings remains to be demonstrated. However,the development of new siRNA delivery strategies and the realization that normal cells may be less sensitive to DEK downregulation are less sensitive to DEK downregulation than their hyperproliferative counterparts, providing a window for therapeutic intervention. The fact that DEK controls the tolerance of tumor cells to genotoxic drugs may also serve as a guide for rational compound selection. better synergize with DEK inhibitors. The observation that DEK is released from apoptotic cells and produces autoantibodies may also provide an alternative approach to assessing drug efficacy in pharmacodynamics. Alternative methods for assessing drug efficacy in pharmacokinetic or pharmacodynamic studies of proapoptotic agents.
References: